FEATURED ARTICLES

• Select, Validate A Generic CHO HCP ELISA For Process Development

  Gain access to practical guidance and an intuitive understanding of how to establish a generic CHO HCP ELISA for your process development.

• The Wild Western Blot: The Good, The Bad, And The Ugly – Session 2

  We analyze causes and preventive strategies relating to common Western blotting pitfalls, such as high background and unspecific or weak bands, and discuss how to find appropriate antibody dilutions without trial and error.

• The Wild Western Blot: The Good, The Bad, And The Ugly – Session 1

  What approach can help ensure high-quality data is generated from every Western blot? What is the best detection method to obtain quantitative data? What key factors generate quantifiable results?

• Coverage Analysis Without A Mock Cell Line

  In this study, we share our development of a coverage assay for a drug substance expressing sample. We demonstrate the removal of a monoclonal antibody drug substance from a production sample.

• Using Pharmalyte® In Capillary Isoelectric Focusing (cIEF) For Charge Variant Analysis Of Monoclonal Antibodies

  Discover how to provide reduction in background interferences speeding up analysis by improving peak integration and improve data quality by providing highly reproducible pI values for protein charge variants.

• Western Blotting Principles And Methods

  Western blotting is an established way to detect and analyze proteins. We share the latest expertise and technology to support your success from sample preparation to analysis.

• Supporting Your Data With Traceability, Accountability, And Integrity

  Is gel and blot imaging a part of your workflow? Understand five ways the Amersham ImageQuant™ 800 GxP imaging system helps you remain compliant.

• Do Not Let HCPs Delay Your Biologics Route To Market

  The stakes are high in biologics development, especially in host cell protein (HCP) analysis. See how optimizing your HCP assays can smooth your route to market.

• FAQs: Challenging Host Cell Protein Assays For Improved Risk Mitigation

  Andrew Hamilton, PhD, Scientist, Imaging & Western Blotting, and Joe Hirano, PhD, Program Manager, Imaging & Western Blotting, answer top questions about challenging host cell protein assays.

• Confidence In HCP Coverage Assays With Differential Gel Approaches

  With more than 20 years of expertise, Cytiva's consumables were developed to support 2D electrophoresis for HCP coverage and give you a solution that provides the highest sensitivity and resolution.

• Future-Proof Your HCP Strategy

  Walk through four questions to help you decide if your HCP analysis data is accurate, robust, and ready for next phase approval.

• Strategy For Host Cell Protein Control

  Critical aspects of therapeutic development and manufacture are host cell protein (HCP) detection, quantitation, and removal from drug substances, to ensure efficacy and prevent immunogenicity. 

• Controlling Host Cell Proteins In Drug Development

  Explore methods to detect HCPs and how to reduce the risk of unexpected HCPs and maximize the efficiency of your HCP management strategy.

• Quantify And Characterize Host Cell Protein With Confidence

  Robust solutions deliver accurate results to prevent HCP underestimation and maintain the pace of biopharmaceuticals development and production.

• Security Of Supply For Critical Reagents Used In HCP Analysis

  For reagents, security of supply is a regulatory requirement, a factor that’s critical to consistently monitoring host cell protein (HCP) during the production of a biologic.